Press Release: Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
Industry News
News|Jun 18 2025
Press Release and Community Statement: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Industry News
Blog|Jun 16 2025
Meet the Community: Mark Kuchmas
Community
Blog|Jun 9 2025
Meet the Community: Luciana Grasiele Nogueira
Community
News|Jun 5 2025
Webinar Recording: Biogen May 2025 Update
FARA News | Industry News
News|Jun 5 2025
Webinar Recording: Lexeo Therapeutics May 2025 Update
FARA News | Industry News
News|Jun 4 2025
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Industry News
News|Jun 3 2025
Gehr Family shares their FA journey, how they raise awareness of Friedreich’s ataxia, and the upcoming Cure FA Soirée with local media outlets